1-7 of 7
Lucille Leong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Nicola R. Hardwick, Paul Frankel, Christopher Ruel, Julie Kilpatrick, Weimin Tsai, Ferdynand Kos, Teodora Kaltcheva, Lucille Leong, Robert Morgan, Vincent Chung, Raechelle Tinsley, Melissa Eng, Sharon Wilczynski, Joshua D.I. Ellenhorn, Don J. Diamond, Mihaela Cristea
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1315–1325.
https://doi.org/10.1158/1078-0432.CCR-17-2709
Published: 14 March 2018
View article titled, p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
Open the PDF for p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy in another window
Includes: Supplementary data
Journal Articles

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D. I. Ellenhorn, Don J. Diamond, Vincent Chung
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4459–4470.
https://doi.org/10.1158/1078-0432.CCR-13-3361
Published: 01 September 2014
View article titled, p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8<sup>+</sup> T-cell Responses
Open the PDF for p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8<sup>+</sup> T-cell Responses in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of a Combination of Yttrium-90–Labeled Anti–Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies

Stephen Shibata, Andrew Raubitschek, Lucille Leong, Marianna Koczywas, Lawrence Williams, Jiping Zhan, Jeffrey Y.C. Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2935–2941.
https://doi.org/10.1158/1078-0432.CCR-08-2213
Published: 15 April 2009
View article titled, A Phase I Study of a Combination of Yttrium-90–Labeled Anti–Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies
Open the PDF for A Phase I Study of a Combination of Yttrium-90–Labeled Anti–Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies in another window
Journal Articles

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Thehang H. Luu, Robert J. Morgan, Lucille Leong, Dean Lim, Mark McNamara, Jana Portnow, Paul Frankel, David D. Smith, James H. Doroshow, David R. Gandara, Ana Aparicio, George Somlo, Carol Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7138–7142.
https://doi.org/10.1158/1078-0432.CCR-08-0122
Published: 03 November 2008
View article titled, A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Open the PDF for A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study in another window
Journal Articles

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Robert J. Morgan, Jr., Timothy W. Synold, Bixin Xi, Dean Lim, Stephen Shibata, Kim Margolin, Roderich E. Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Merry Tetef, Paul Lin, Benjamin Paz, Mariana Koczywas, Lawrence Wagman, David Chu, Paul Frankel, Susan Stalter, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1232–1237.
https://doi.org/10.1158/1078-0432.CCR-06-1735
Published: 22 February 2007
View article titled, Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Open the PDF for Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity in another window
Journal Articles

Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics

Robert J. Morgan, Jr., James H. Doroshow, Timothy Synold, Dean Lim, Stephen Shibata, Kim Margolin, Roderich Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Paul Lin, Benjamin Paz, David Chu, Paul Frankel, Susan Stalter
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5896–5901.
Published: 15 December 2003
View article titled, Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: <subtitle>Dose-Limiting Toxicity and Pharmacokinetics</subtitle>
Open the PDF for Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: <subtitle>Dose-Limiting Toxicity and Pharmacokinetics</subtitle> in another window
Journal Articles

Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies

Merry L. Tetef, Timothy W. Synold, Warren Chow, Lucille Leong, Kim Margolin, Robert Morgan, James Raschko, Stephen Shibata, George Somlo, Yun Yen, Susan Groshen, Kay Johnson, Heinz-Josef Lenz, David Gandara, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1569–1576.
Published: 01 June 2001
View article titled, Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies
Open the PDF for Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies in another window